June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Pharmacokinetics of I-124 aflibercept after intravitreal injection using PET/CT imaging after lensectomy in a rabbit model
Author Affiliations & Notes
  • John Christoforidis
    Department of Ophthalmology and Vision Science, University of Arizona College of Medicine, Tucson, AZ
  • Michelle Williams
    Radiology, The Ohio State University College of Medicine, Columbus, OH
  • Frank Epitropoulos
    Ophthalmology, The Ohio State University College of Medicine, Columbus, OH
  • Michael Knopp
    Radiology, The Ohio State University College of Medicine, Columbus, OH
  • Footnotes
    Commercial Relationships John Christoforidis, None; Michelle Williams, None; Frank Epitropoulos, None; Michael Knopp, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4891. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John Christoforidis, Michelle Williams, Frank Epitropoulos, Michael Knopp; Pharmacokinetics of I-124 aflibercept after intravitreal injection using PET/CT imaging after lensectomy in a rabbit model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4891.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine the anatomic characteristics and pharmacokinetic properties of intravitreally-placed I-124-aflibercept after pars plana lensectomy and to compare these with non-operated control eyes in a rabbit model.

Methods: Three Dutch-belted rabbits underwent pars plana lensectomy and four served as non-surgical controls. Twelve days after surgery each rabbit underwent intravitreal injection in one eye with I-124-aflibercept. Serial imaging with PET-CT were obtained on days 0, 2, 5, 7, 14, 21, 28 and 35. Radioactivity emission was measured in becquerels/ml (Bq/ml) and was used to calculate half-lives for each agent.

Results: The intravitreally placed radiolabeled agents were contained within the vitreous cavity for the duration of the study. The average clearance half-lives with standard error and 95% confidence intervals for I-124-aflibercept after correction for radioactive decay was 4.58 +/- 0.07 (4.28, 4.87) days in unoperated eyes and 1.95 +/- 0.02 (1.88, 2.02) (p<0.0001) days after lensectomy.

Conclusions: Intravitreal clearance of aflibercept was significantly increased following lensectomy as compared to non-surgical controls. Consideration for more frequent intravitreal anti-VEGF dosing regimens may be made for patients who are aphakic.

Keywords: 550 imaging/image analysis: clinical • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×